期刊
JOURNAL OF CLINICAL INVESTIGATION
卷 121, 期 2, 页码 500-507出版社
AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI45130
关键词
-
资金
- NIH National Institute of Neurological Disorders and Stroke [38194]
- CHDI
- NIH [DK32520]
Huntington disease is an autosomal dominant neurodegenerative disorder caused by a toxic expansion in the CAG repeat region of the huntingtin gene. Oligonucleotide approaches based on RNAi and antisense oligonucleotides provide promising new therapeutic strategies for direct intervention through reduced production of the causative mutant protein. Allele-specific and simultaneous mutant and wild-type allele-lowering strategies are being pursued with local delivery to the brain, each with relative merits. Delivery remains a key challenge for translational success, especially with chronic therapy. The potential of disease-modifying oligonucleotide approaches for Huntington disease will be revealed as they progress into clinical trials.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据